- Home
- LXEH vs IXHL Comparison
LXEH vs IXHL Comparison
Compare LXEH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- IXHL
- Stock Information
- Founded
- LXEH 2001
- IXHL 2001
- Country
- LXEH China
- IXHL Australia
- Employees
- LXEH N/A
- IXHL N/A
- Industry
- LXEH Other Consumer Services
- IXHL
- Sector
- LXEH Real Estate
- IXHL
- Exchange
- LXEH Nasdaq
- IXHL Nasdaq
- Market Cap
- LXEH 55.2M
- IXHL 54.5M
- IPO Year
- LXEH 2020
- IXHL N/A
- Fundamental
- Price
- LXEH $2.43
- IXHL $0.53
- Analyst Decision
- LXEH
- IXHL
- Analyst Count
- LXEH 0
- IXHL 0
- Target Price
- LXEH N/A
- IXHL N/A
- AVG Volume (30 Days)
- LXEH 4.3M
- IXHL 114.5M
- Earning Date
- LXEH 09-26-2025
- IXHL 11-13-2025
- Dividend Yield
- LXEH N/A
- IXHL N/A
- EPS Growth
- LXEH N/A
- IXHL N/A
- EPS
- LXEH N/A
- IXHL N/A
- Revenue
- LXEH $4,493,795.00
- IXHL $98,000.00
- Revenue This Year
- LXEH N/A
- IXHL $2,538.49
- Revenue Next Year
- LXEH N/A
- IXHL $249.95
- P/E Ratio
- LXEH N/A
- IXHL N/A
- Revenue Growth
- LXEH N/A
- IXHL N/A
- 52 Week Low
- LXEH $1.12
- IXHL $0.08
- 52 Week High
- LXEH $50.08
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- LXEH 63.64
- IXHL 48.05
- Support Level
- LXEH $2.26
- IXHL $0.51
- Resistance Level
- LXEH $2.69
- IXHL $0.59
- Average True Range (ATR)
- LXEH 0.22
- IXHL 0.05
- MACD
- LXEH 0.04
- IXHL -0.01
- Stochastic Oscillator
- LXEH 73.20
- IXHL 12.99
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.